ArticleInternational journal of molecular sciences2026
An Integrated Text Mining Approach for Discovering Pharmacological Effects, Drug Combinations, and Repurposing Opportunities of ACE Inhibitors.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The rapidly expanding body of biomedical literature encompasses a wealth of information concerning the pharmacological effects, mechanisms of action, adverse reactions, and repurposing potential of small-molecule therapeutics. Nevertheless, the systematic extraction and integration of this knowledge continue to pose substantial challenges. In this study, we propose an integrated text-mining framework for the automated extraction and structured representation of information on the biological activities of low-molecular-weight compounds, exemplified by angiotensin-converting enzyme (ACE) inhibitors as a representative pharmacological class. A corpus comprising over 20,000 PubMed titles and abstracts reporting in vitro, in vivo, and clinical investigations of ACE inhibitors was assembled. Chemical compounds, proteins/genes, and diseases were recognized using a previously developed named entity recognition model based on conditional random fields. Entity-level associations were extracted at the sentence level through a rule-based approach employing manually curated pattern phrases, followed by normalization via automated queries to PubChem, UniProt, and the Human Disease Ontology. The proposed methodology facilitated the extraction of approximately 22,000 unique and normalized associations encompassing drug-target, drug-disease, and drug-drug relationships. In addition to confirming well-established therapeutic effects and clinically recognized drug combinations, the analysis identified underexplored pharmacological activities of ACE inhibitors, including antineoplastic, antifibrotic, and neuropsychiatric properties, along with mechanistic associations involving matrix metalloproteinases and neurotrophic signaling pathways. Collectively, these findings underscore the potential of automated literature mining to advance systematic knowledge integration and data-driven hypothesis generation in the contexts of drug repurposing and safety evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.